ProCE Banner Activity

Phase II Study: Frontline Cytarabine and Idarubicin + Nivolumab in Newly Diagnosed AML

Slideset Download
Conference Coverage
Study reported median event-free survival of 8.3 months in patients receiving nivolumab plus cytarabine and idarubicin with manageable safety profile.

Released: December 19, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology